Last €0.07 EUR
Change Today -0.003 / -4.17%
Volume 4.0K
DNR On Other Exchanges
Symbol
Exchange
OTC US
Stuttgart
As of 11:14 AM 12/23/14 All times are local (Market data is delayed by at least 15 minutes).

dendreon corp (DNR) Snapshot

Open
€0.07
Previous Close
€0.07
Day High
€0.07
Day Low
€0.06
52 Week High
01/13/14 - €2.54
52 Week Low
12/17/14 - €0.05
Market Cap
11.0M
Average Volume 10 Days
16.1K
EPS TTM
--
Shares Outstanding
158.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DENDREON CORP (DNR)

dendreon corp (DNR) Related Businessweek News

No Related Businessweek News Found

dendreon corp (DNR) Details

Dendreon Corporation, a biotechnology company, focuses on the discovery, development, and commercialization of novel therapeutics to enhance cancer treatment options for patients. Its product portfolio includes active cellular immunotherapies and a small molecule product candidate that could be applicable to treating various types of cancers. The company offers PROVENGE, an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, and castrate-resistant prostate cancer. Its product candidates under research and development includes DN24-02, an investigational active cellular immunotherapy, which is in Phase II clinical trial for the treatment of patients with bladder, breast, ovarian, and other solid tumors expressing HER2/neu; carbonic anhydrase 9, an antigen expressed in renal cell carcinoma; carcinoembryonic antigen, an antigen expressed in colorectal and other cancers; and Transient Receptor Potential, sub-family M 8, a small molecule that has completed Phase I clinical trial to treat various types of cancers. Dendreon Corporation was founded in 1992 and is headquartered in Seattle, Washington. On November 10, 2014, Dendreon Corp. along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

710 Employees
Last Reported Date: 11/10/14
Founded in 1992

dendreon corp (DNR) Top Compensated Officers

Interim Chief Financial Officer, Principal Ac...
Total Annual Compensation: $354.1K
Compensation as of Fiscal Year 2013.

dendreon corp (DNR) Key Developments

Nasdaq Files Form 25-NSE With Securities And Exchange Commission To Delist Securities Of Dendreon Corporation

As previously announced, on November 10, 2014, Dendreon Corporation and its wholly owned subsidiaries, Dendreon Holdings, LLC, Dendreon Distribution, LLC and Dendreon Manufacturing, LLC filed voluntary petitions for relief (Chapter 11 Cases) under Chapter 11 of Title 11 of the United States Code (Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware. On November 10, 2014, as previously disclosed, the company received a Staff Delisting Determination letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq) indicating that, in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, the Staff had determined that the company’s securities would be delisted from Nasdaq unless the company requested an appeal of such determination. As the company did not request a hearing before the Nasdaq Hearings Panel by November 17, 2014, trading of the company’s securities on Nasdaq was suspended at the opening of business on November 19, 2014. On December 11, 2014, Nasdaq filed a Form 25-NSE with the Securities and Exchange Commission, which will remove the company’s securities from listing and registration on Nasdaq, effective at the opening of the trading session on December 22, 2014. Since its suspension from Nasdaq, the company’s common stock has been quoted on the OTC Pink Marketplace.

Nasdaq Stock Market To File Form 25 With Securities And Exchange Commission To Complete Delisting Of Dendreon Corporation

The Nasdaq Stock Market announced that it will delist the common stock of Dendreon Corporation. Dendreon Corporation's stock was suspended on November 19, 2014 and has not traded on Nasdaq since that time. Nasdaq will file a Form 25 with the Securities and Exchange Commission to complete the delisting of the company. The delisting becomes effective ten days after the Form 25 is filed.

Dendreon Corp.(OTCPK:DNDN.Q) dropped from Russell 2000 Index

Dendreon Corp. will be removed from the Russell 2000 Index.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DNR:GR €0.07 EUR -0.003

DNR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for DNR.
View Industry Companies
 

Industry Analysis

DNR

Industry Average

Valuation DNR Industry Range
No financial data is available for DNR.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DENDREON CORP, please visit www.dendreon.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.